Lenalidomide and Dexamethasone (Rd) versus Clarithromycin [Biaxin®]/Lenalidomide [Revlimid®]/Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma
Clinical Trial Details
This research study is for men and women with newly diagnosed, previously untreated multiple myeloma.
The purpose of this study is to observe the how well the different combinations of study drugs work as therapy for patients with newly diagnosed, transplant ineligible, previously untreated multiple myeloma.
The study will be done in two arms:
BiRd Arm: - Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle - Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle - Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Rd Arm: - Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle - Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
Subjects will be treated in 28-day cycles and may continue treatment as long as they are responding to therapy and not experiencing unacceptable side effects or disease progression. There will be an evaluation at the end of each cycle. Participants will be in the study until disease progression or unacceptable toxicity.
Men and women >65 years at the time of signing the consent form
Confirmed diagnosis of multiple myeloma that has never before been treated
No prior anti-myeloma treatment therapy within 14 days prior to initiation of study treatment
Subject has no prior history of other malignancies unless disease free for >5 years
Subject has not had a myocardial infarction within 6 months prior to enrollment
Detailed eligibility reviewed when you contact the study team